Fundz

Nuwellis

Biotechnology, Health Care, Medical · 60 employees

The Aquadex SmartFlow® System, our ground-breaking and proven ultrafiltration solution, gently removes fluid and restores balance to patients suffering from fluid overload. Our technology provides reliable and predictable therapy solutions that are flexible in application, gentle on the patient and designed to reduce healthcare costs associated with treating fluid overload.

Funding history

  • Series seed — $3.8M — Nov 2024
  • Series seed — $1.7M — May 2020
  • Series seed — $2.2M — Apr 2020
  • Series seed — $1.2M — Mar 2020
  • Series seed — $1.4M — Nov 2019

Recent signals

  • Jun 08, 2026: SEC 8-K (7.01): On June 8, 2026, Nuwellis, Inc. announced the successful closing of its registered public offering, generating gross proceeds of approximately $6,000,000 before deducting placement agent fees and other associated expenses. Following the offering, the total shares of common stock outstanding increased to 12,750,321 due to the exercise of pre-funded warrants by investors in the transaction. This funding is expected to support Nuwellis's ongoing operational activities and strategic initiatives. The filing serves as Regulation FD disclosure to inform investors and stakeholders about this significant financial event.
  • Apr 24, 2026: Nuwellis, Inc. Settles Dispute with E.F. Hutton & Co.
  • Apr 24, 2026: SEC 8-K (8.01): On April 24, 2026, Nuwellis, Inc. entered into a Settlement Agreement with E.F. Hutton & Co. regarding a lawsuit initiated by Hutton alleging breach of engagement related to the Company's registered securities offerings. As part of the Settlement Agreement, Nuwellis agreed to pay a total of $204,000 to Hutton within five days, without any admission of liability. This settlement resolves the legal dispute and includes a mutual release of claims, thus potentially allowing Nuwellis to focus on its business without further legal distractions. The financial impact of the settlement is noted as significant due to the allocation of funds that could affect liquidity.
  • Mar 17, 2026: Acquired Nuwellis acquires Rendiatech for kidney monitoring tech
  • Feb 24, 2026: SEC 8-K (5.02): On February 24, 2026, Nuwellis, Inc. expanded its Board of Directors from five to seven members by appointing Martin J. Emerson and David A. McDonald to fill the new vacancies. Mr. Emerson has been classified as a Class I director with a term ending at the company's 2026 annual stockholders' meeting, and he has been deemed 'independent' per Nasdaq standards. This expansion may enhance the governance structure and oversight of Nuwellis, potentially impacting strategic decisions moving forward.
  • Feb 24, 2026: SEC 8-K (5.02): Nuwellis, Inc. announced on February 24, 2026, a significant change in its corporate governance by expanding its Board of Directors from five to seven members. The newly appointed directors, Martin J. Emerson and David A. McDonald, will fill the vacancies created by this expansion. Mr. Emerson has been designated as a Class I director with a term set to expire at the annual meeting of stockholders in 2026, and he has been confirmed as 'independent' according to Nasdaq listing standards. This strategic move is aimed at enhancing the Board's effectiveness and governance structure, aligning with best practices in corporate management.
  • Jan 21, 2026: SEC 8-K (5.02): On January 21, 2026, Nuwellis, Inc. announced the resignation of three board directors: Dave McDonald, Mike McCormick, and Dr. Maria Costanzo. Their resignations were not due to any disagreements with the company's operations or policies. Following these resignations, the Board decided to reduce its size from six to five members. Additionally, on the same day, Katharyn Field was appointed to the Board as a Class I director, with her term set to expire as per the usual rotation for board members. This restructuring could indicate a strategic shift in governance at Nuwellis, Inc.
  • Jul 02, 2025: Nuwellis Appoints John Erb as Chief Executive Officer

See plans & pricing → Track Nuwellis’s funding, hiring, and signals — with verified contacts — on Fundz.